Ranibizumab and the Risk of Arterial Thromboembolic Events
Status:
Terminated
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The investigators assume that ranibizumab might be dangerous in patients with history of
coronary artery disease or cerebrovascular events. The main objective of study is to reveal
contraindications for ranibizumab prescription in patients with history of coronary artery
disease and cerebrovascular events. Moreover, an association between management with
ranibizumab and ATE rate in healthy above 50 years old persons is a concern of great interest
as well.
Phase:
Phase 4
Details
Lead Sponsor:
Ural Medical University Ural State Medical University
Collaborators:
De Haar Research Foundation Ural Institute of Cardiology